LifeMD Inc (NASDAQ:LFMD) Stock Plummets Over 22% After Q3 2025 Earnings Miss
By Mill Chart
Last update: Nov 18, 2025
LifeMD Inc (NASDAQ:LFMD) reported its third quarter 2025 financial results, revealing a performance that fell short of analyst expectations on key profitability and revenue metrics. The market reaction was swift and severe, with the stock experiencing a dramatic decline in after-hours trading.
Third Quarter 2025 Financial Results
The company's Q3 2025 earnings report presented a mixed picture, with top-line growth overshadowed by a significant miss on earnings. The reported figures compared to analyst estimates highlight the core issues that appear to have concerned investors.
- Revenue: The company reported $60.2 million in total revenue, marking a 13% year-over-year increase. However, this figure came in below the analyst consensus estimate of $63.3 million.
- Earnings Per Share (EPS): LifeMD reported a non-GAAP EPS of -$0.10. This was more than double the loss anticipated by analysts, who had estimated an EPS of -$0.048.
While the company highlighted a 20% rise in adjusted EBITDA to $5.1 million and an 18% growth in its core Telehealth revenue segment to $47.3 million, these positive developments were not sufficient to offset the headline misses.
Market Reaction and Performance
The immediate market response to the earnings release was decisively negative. Investor sentiment was clearly reflected in the stock's after-market performance, which showed a decline of over 22%. This sharp drop suggests that the market was focused on the company's failure to meet profitability and revenue targets for the quarter. This recent performance adds to a challenging period for the stock, which has seen declines over the past month.
Press Release Summary and Outlook
The earnings press release from LifeMD emphasized the company's year-over-year revenue growth and the strength of its Telehealth platform. It detailed the expansion of services across primary care and specialized treatments. Notably, the provided press release did not include a specific financial outlook or guidance for the upcoming quarter or the remainder of the fiscal year. The absence of this forward-looking information means it cannot be directly compared to the existing analyst estimates for Q4 and full-year 2025, which project sales of $64.3 million and $258.1 million, respectively.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the data available on the LifeMD earnings and estimates page.
The third quarter results for LifeMD underscore the challenges of balancing growth investments with profitability. The market's negative reaction, as seen in the significant after-hours sell-off, points to investor disappointment regarding the earnings and revenue misses, indicating that meeting growth expectations is critical for maintaining market confidence in the competitive telehealth sector.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services. The information presented should not be used as the sole basis for any investment decision.
